Close Window

Digital Look Email A Friend

Syncona NAV rises as Beacon breakthrough boosts valuation

Published by Benjamin Chiou on 12th November 2026

(Sharecast News) - Life sciences investor Syncona reported a 3% increase in net asset value per share in the first half, driven by positive clinical trial results from portfolio company Beacon Therapeutics, as it reiterated plans to return at least £250m to shareholders.

URL: http://www.digitallook.com/dl/news/story/36347229/...

Email this article to your friends
NOTE: These email addresses will be used to email the information on your behalf and will not be collected by Digital Look for any marketing purposes.